Compare RELL & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RELL | OTLK |
|---|---|---|
| Founded | 1947 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.1M | 249.6M |
| IPO Year | 2004 | 2016 |
| Metric | RELL | OTLK |
|---|---|---|
| Price | $20.74 | $0.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | ★ $20.50 | $5.03 |
| AVG Volume (30 Days) | 184.6K | ★ 3.4M |
| Earning Date | 10-07-2026 | 08-14-2026 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $228,564,000.00 | $8,146,123.00 |
| Revenue This Year | $9.68 | N/A |
| Revenue Next Year | $6.86 | $6,355.64 |
| P/E Ratio | $230.96 | ★ N/A |
| Revenue Growth | ★ 9.41 | N/A |
| 52 Week Low | $9.37 | $0.16 |
| 52 Week High | $23.15 | $2.54 |
| Indicator | RELL | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 70.08 | 40.15 |
| Support Level | $15.41 | $0.60 |
| Resistance Level | $21.74 | $0.70 |
| Average True Range (ATR) | 0.87 | 0.04 |
| MACD | 0.38 | 0.00 |
| Stochastic Oscillator | 80.21 | 37.58 |
Richardson Electronics Ltd is a world-wide manufacturer of engineered solutions, green energy products, power grid and microwave tubes, and related consumables; power conversion and RF and microwave components including green energy solutions; tubes for diagnostic imaging equipment; and customized display solutions. It serve customers in alternative energy, healthcare, aviation, broadcast, communications, industrial, marine, medical, military, scientific, and semiconductor markets. Its products and services include design-in support, systems integration, prototype design and manufacturing, testing, logistics, etc. Its segments are Power and Microwave Technologies (PMT), Green Energy Solutions (GES), and Canvys. Majority of Sales is from PMT. Majority of sales is from North America.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.